Pacts In Medtech, July/August 2016
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, this new bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. This month we highlight deals announced in July and August 2016.
You may also be interested in...
New GSK-Verily JV Aims For Smart, 'Grain Of Rice' Neuromod Tech
Galvani Bioelectronics, the new joint venture between Google’s health-care spinoff Verily and drug giant GSK, will develop a new generation of "bioelectronic medicines" – neuromodulating therapies to treat a wide range of chronic diseases. Brian Otis, CTO of Verily, tells Medtech Insight how the devices that will come out of Galvani differ from existing neuromodulation technologies.
Dealmaking Quarterly Statistics, Q1 2023
During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.
Deals In Depth: April 2023
Six $1bn+ alliances were penned in April. Topping the list was a potential $2.55bn multi-year deal between Proxygen and Merck to jointly identify and develop molecular glue degraders against multiple therapeutic targets. The collaboration will allow Proxygen to leverage its platform and advance Merck's understanding in molecular glue degraders to open new avenues in the pursuit of novel therapeutics.